A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

BJU International

Volumn 108, Issue 5, 2011, Pages 679-686

  Schöffski, Patrick ^a   Garcia, Jorge A ^b   Stadler, Walter M ^c   Gil, Thierry ^d   Jonasch, Eric ^e   Tagawa, Scott T ^f   Smitt, Melanie ^g   Yang, Xinqun ^g   Oliner, Kelly S ^g   Anderson, Abraham ^g   Zhu, Min ^g   Kabbinavar, Fairooz ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g AMGEN INC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMG 102; c Met; clear cell renal cell carcinoma; hepatocyte growth factor; papillary renal cell carcinoma; renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLEAR CELL CARCINOMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OPEN STUDY; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80051991655     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09947.x     Document Type: Article

References (30)

1. Scelo G, Brennan P,. The epidemiology of bladder and kidney cancer. Nat Clin Pract Urol 2007; 4: 205-17 (Pubitemid 46567153)
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 (Pubitemid 40372904)
3. McLaughlin JK, Lipworth L, Tarone RE,. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006; 33: 527-33 (Pubitemid 44511980)
4. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
5. Escudier B, Pluzanska A, Koralewski P, et al,. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11 (Pubitemid 350296300)
6. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34 (Pubitemid 46089673)
7. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
8. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
9. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81 (Pubitemid 46849157)
10. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56
11. Giubellino A, Linehan WM, Bottaro DP,. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9: 785-93
12. Pisters LL, El-Naggar AK, Luo W, Malpica A, Lin S-H,. C-Met proto-oncogene expression in benign and malignant human renal tissues. J Urol 1997; 158: 724-8
13. Natali PG, Prat M, Nicotra MR, et al,. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996; 69: 212-7 (Pubitemid 26233301)
14. Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T,. Biological role of HGF/Met pathway in renal cell carcinoma. J Urol 1999; 161: 990-7 (Pubitemid 29422421)
15. Koochekpour S, Jeffers M, Wang PH, et al,. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902-12 (Pubitemid 29399295)
16. Nakaigawa N, Yao M, Baba M, et al,. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 2006; 66: 3699-705
17. Tanimoto S, Fukumori T, El-Moula G, et al,. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest 2008; 55: 106-11 (Pubitemid 351643600)
18. Schmidt L, Duh FM, Chen F, et al,. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73 (Pubitemid 27198158)
19. Schmidt L, Junker K, Nakaigawa N, et al,. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-50 (Pubitemid 29192711)
20. Michieli P, Basilico C, Pennacchietti S, et al,. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999; 18: 5221-31 (Pubitemid 29460658)
21. Gordon MS, Sweeney CS, Mendelson DS, et al,. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16: 699-710
22. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16
23. Green SJ, Benedetti J, Crowley J,. Clinical Trials in Oncology, 1st edn. London: Chapman & Hall, 1997
24. Rini BI, Michaelson MD, Rosenberg JE, et al,. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-8
25. Rini BI, Wilding G, Hudes G, et al,. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4462-8
26. Shepard DR, Rini BI, Garcia JA, et al,. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26: abstr 5123
27. Reardon DA, Cloughsey TF, Raizer JJ, et al,. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: abstr 2051
28. Rosen PJ, Sweeney CJ, Park DJ, et al,. A phase 1b study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 2677-787
29. Srinivasan R, Linehan WM, Vaishampayan U, et al,. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2009; 27: abstr 5103
30. Goldberg J, Demetri GD, Choy E, et al,. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol 2009; 27: abstr 10502